Kaplan-Meier survival plot demonstrating 60-day mortality for patients with acute respiratory distress syndrome stratified by quartile of baseline adiponectin (APN) level for full cohort (N = 816).

<p>APN Quartile 1: 95–3589 pg/ml; Quartile 2: 3630–7241 pg/ml; Quartile 3: 7248–13212; Quartile 4: 7248–13212.</p

Kaplan-Meier survival plots demonstrating 60-day mortality for patients with acute respiratory distress syndrome stratified by quartile of baseline adiponectin (APN) level for patients with indirect lung injury (N = 322).

<p>A significant interaction was demonstrated (p = 0.016) for the association between baseline APN levels and mortality based on whether the mechanism of acute respiratory distress syndrome was presumed to be from “direct” pulmonary injury (eg., pneumonia, aspiration) or “indirect” injury from extra-pulmonary etiologies (eg., urosepsis, trauma, transfusion).</p

Multivariable-adjusted model of factors associated with baseline adiponectin levels.

<p>Model N = 666, Model R² = 0.097.</p><p>Multivariable-adjusted model of factors associated with baseline adiponectin levels.</p

Pulmonary artery catheter hemodynamics and adiponectin levels.

<p>Values are medians (Inter-Quartile Range).</p><p>Trans-pulmonary pressure gradient: Mean pulmonary artery pressure-Pulmonary artery occlusion pressure.</p><p>*p<0.1 and selected for inclusion in multivariable models.</p><p>Pulmonary artery catheter hemodynamics and adiponectin levels.</p

Epigenomic marks indicating enhancer activity at the 5q22 locus.

<p>Histone marks in samples from the ROADMAP Epigenomics Project at the enhancer overlapping the lead SNP rs9885413 in heart tissue (left ventricle) and in tissues with evidence of an active enhancer at the locus. Histone marks are monomethylation (H3K4Me1) of the fourth residue (lysine) and acetylation of the 27th residue (H3K27Ac) of histone H3. Positions refer to NCBI build 36.</p

Association of genetic polymorphisms with HF mortality.

<p>Association of genetic polymorphisms with HF mortality.</p

Regional association plot for HF mortality at the 5q22 locus.

<p>The plot covers the genomic region from 450 kb upstream of the SNP to 650 kb downstream. Diamonds represent SNPs. The large black diamond represents the SNP with the lowest <i>P</i>-value (rs9885413), with the <i>P</i>-value from the combined meta-analysis presented. Diamond color represents strength of pairwise correlation with the strongest SNP. Red represents r² ≥ 0.8, orange represents r² 0.5–0.8, yellow represents r² 0.2–0.5, and white represents r² < 0.2. Recombination rate is plotted in the background and known genes are represented in the bottom of the plot. Positions refer to NCBI build 36. SNP correlations and recombination rates were obtained from HapMap release 22.</p

Characteristics of cohorts in stage 1.

<p>Characteristics of cohorts in stage 1.</p

Plots show the individual interaction p-values based on Stage I (indicated as solid dots) or Stage I + Stage II meta-analysis (indicated as outlined dots with “+” symbol) against their genomic position for the combined cardiovascular disease (CVD) outcome for the four antihypertensive medication exposures: (a) Angiotensin-converting enzyme (ACE) inhibitors, (b) Beta-blockers, (c) Calcium Channel Blockers, and (d) Thiazide Diuretics.

<p>Within each chromosome, shown on the x-axis, the results are plotted left to right from the p-terminal end. The nearest genes are indicated for variants with an interaction p-value less than 1×10⁻⁵ in the meta-analysis.</p

Characteristics of Study Participants.

<p>Age indicates mean age. Model indicates analysis method: C, Cox proportional hazards regression; L, logistic regression. For prevalence of antihypertensive medication use ACE indicates Angiotensin-converting enzyme inhibitor (or angiotensin receptor blocker); BB, beta-blocker; CCB, calcium channel blocker; Diuretics, thiazide diuretics.For studies analyzed with logistic regression, summaries are provided separately for cases and controls.</p><p>Characteristics of Study Participants.</p